Conclusions
To conclude, FCN-159 was well tolerated in patients with NF-1-related PN and demonstrated promising anti-tumor activity. The proposed RP2D for FCN‑159 was identified as 8 mg. The present findings support further investigation of FCN-159 as a treatment for patients with NF1–related PN, a group for whom the only intervention, surgery, is of limited efficacy.